. Author manuscript; available in PMC: 2010 Apr 30.

Published in final edited form as: J Empir Res Hum Res Ethics. 2008 Sep;3(3):57–68. doi: 10.1525/jer.2008.3.3.57

TABLE 4.

Purpose of Trial Mentioned by Participants by Phase Trial in which Offered Enrollment (N = 65).

	Phase I	Phase II	TOTAL	p-value
Mentioned safety/dosing	17%	7%	12%	0.200
Mentioned benefit	60%	83%	71%	0.039
Mentioned both Safety/dosing and personal benefit	6%	3%	5%	0.648